These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16900222)

  • 21. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of prognosis to lamivudine in patients with spontaneous reactivation of hepatitis B virus-related acute-on-chronic liver failure: using virologic response at week 4.
    Xiang-Hui Y; Lang X; Yan Z; Li Z; Xiao-Feng S; Hong R
    Eur J Intern Med; 2014 Nov; 25(9):860-4. PubMed ID: 25439100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of hepatitis B virus-associated membranous nephropathy: lamivudine era versus post-lamivudine era.
    Moon JY; Lee SH
    Korean J Intern Med; 2012 Dec; 27(4):394-6. PubMed ID: 23269879
    [No Abstract]   [Full Text] [Related]  

  • 24. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management.
    Locarnini S
    J Gastroenterol Hepatol; 2010 Apr; 25(4):649-51. PubMed ID: 20492319
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of hepatitis B virus-associated nephropathy.
    Elewa U; Sandri AM; Kim WR; Fervenza FC
    Nephron Clin Pract; 2011; 119(1):c41-9; discussion c49. PubMed ID: 21677438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
    Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
    AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations.
    Tong CY; Mullen JE; Wong T
    J Antimicrob Chemother; 2009 Oct; 64(4):875-7. PubMed ID: 19671587
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy.
    Pai SB; Pai RB; Schinazi RF
    Panminerva Med; 2003 Sep; 45(3):165-73. PubMed ID: 14618114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early detection of hepatitis B drug resistance: implications for patient management.
    Sablon E; Shapiro F; Zoulim F
    Expert Rev Mol Diagn; 2003 Sep; 3(5):535-47. PubMed ID: 14510175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient.
    Thabut D; Thibault V; Benhamou Y; Bernard B; Aubron-Olivier C; Poynard T; Di Martino V
    AIDS; 2001 Dec; 15(18):2463-4. PubMed ID: 11774835
    [No Abstract]   [Full Text] [Related]  

  • 32. [New antiviral agent. Hepatitis B therapy with slight resistance risk].
    MMW Fortschr Med; 2003 Dec; 145(51-52):40. PubMed ID: 14974332
    [No Abstract]   [Full Text] [Related]  

  • 33. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
    Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical prognosis of drug-susceptible chronic hepatitis B virus patients at year 5 of lamivudine monotherapy].
    Zhang YR; Yan WC; Zhang YP; Jiao JZ; Zhang T; Li XL; Wu LY; Wei SF
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):63-4. PubMed ID: 22489300
    [No Abstract]   [Full Text] [Related]  

  • 36. Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection.
    Arcaini L; Merli M; Rattotti S; Bruno R; Vercelli A; Lucioni M; Riboni R; Paulli M
    J Clin Oncol; 2011 Jun; 29(18):e543-5. PubMed ID: 21482990
    [No Abstract]   [Full Text] [Related]  

  • 37. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
    Mutimer D
    J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
    [No Abstract]   [Full Text] [Related]  

  • 38. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!
    Angus P; Locarnini S
    Antivir Ther; 2004 Apr; 9(2):145-8. PubMed ID: 15134176
    [No Abstract]   [Full Text] [Related]  

  • 39. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou Y; Tubiana R; Thibault V
    N Engl J Med; 2003 Jan; 348(2):177-8. PubMed ID: 12519935
    [No Abstract]   [Full Text] [Related]  

  • 40. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
    Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.